Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences is attractive because its core HIV franchise is still gaining momentum, with Biktarvy slightly above expectations at $3.361 billion, Descovy showing strong U.S. demand, and HIV growth now expected at 8%, all of which support durable cash flows and pricing power. The acceptance of oral Yeztugo for HIV PrEP adds another potential growth layer by broadening the brand into a longer-acting oral option and strengthening its position against emerging competitors, while early persistency trends and $1 billion FY26 guidance suggest meaningful adoption. Beyond virology, the company’s expanding oncology portfolio, including Yescarta/Tecartus, Trodelvy, and anito-cel, adds pipeline optionality and a path to diversify revenue growth as newer assets mature.

Gilead Sciences is challenged by a weakening core as HIV and HCV face generic entrants, competition, and pricing pressure, while U.S. government cuts to HIV program funding could further pressure the franchise. Its next-wave HIV assets also carry execution risk, since Yeztugo could launch slower than expected, bic/len may lack clear advantages versus Biktarvy, and higher-dose 3242 still faces tolerability uncertainty. The oncology push adds risk rather than certainty, with concerns about slower Yescarta uptake, limited near-term role for anito-cel, and uneven Trodelvy data, all of which could undermine earnings durability and support for valuation.